Showing results (91-100 of 207) with videos related to

Sort By:
Pageof 21
Journal of Gastroenterology and Hepatology|April 20, 1999
Characterization of anti-hepatitis C virus-positive sera not genotyped by restriction fragment length polymorphism or serologyR G Gish, K Qian, L Brooks, et al.
The American Journal of Gastroenterology|September 1, 1993
Liver transplantation for patients with alcoholism and end-stage liver diseaseR G Gish, A H Lee, E B Keeffe, et al.
JHEP Reports : Innovation in Hepatology|September 13, 2023
On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis BZeyuan Yang, Ramsey C Cheung, Amit S Chitnis, et al.
BMJ Open Gastroenterology|October 14, 2015
Predictors of hepatic decompensation after TACE for hepatocellular carcinomaMohamed A S Kohla, Mai I Abu Zeid, Mohamed Al-Warraky, et al.
Current Hepatology Reports|December 6, 2016
Future Therapy for Hepatitis B Virus: Role of ImmunomodulatorsEdward A Pham, Ryan B Perumpail, Benjamin J Fram, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 18, 2012
Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis BRobert G Gish, Margaret D Clark, Steve D Kane, et al.
Oncogene|May 1, 1993
Regulation of c-Src tyrosine kinase activity by the Src SH2 domainX Liu, S R Brodeur, G Gish, et al.
Journal of Hepatology|November 17, 2009
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patientsPatrick Marcellin, Robert G Gish, Norman Gitlin, et al.
Journal of Virology|May 22, 2002
Characteristics of hepatitis B virus isolates of genotype G and their phylogenetic differences from the other six genotypes (A through F)Hideaki Kato, Etsuro Orito, Robert G Gish, et al.
Alimentary Pharmacology & Therapeutics|April 1, 2008
Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysisD L Veenstra, D E Spackman, A Di Bisceglie, et al.
Pageof 21